HQP 1351

Drug Profile

HQP 1351

Alternative Names: APG 1351; HQP1351

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic myeloid leukaemia; Gastrointestinal stromal tumours

Most Recent Events

  • 26 Jul 2017 Phase-I clinical trials in Gastrointestinal stromal tumours in China (unspecified route) (Ascentage Pharma pipeline, July 2017)
  • 10 Jan 2017 Phase I trials in Chronic myeloid leukaemia in China (unspecified route) (Ascentage Pharma pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top